Biotech

Biotech Elaine Chen

STAT Plus: AbbVie Parkinson’s drug helps improve symptoms in late-stage study

Biotech Allison DeAngelis

STAT Plus: ARCH Venture Partners raises $3 billion for a new biotech fund

Adam's Take Adam Feuerstein

STAT Plus: Why Biohaven will test the FDA’s regulatory limits  

Adam's Take Adam Feuerstein

STAT Plus: Gene therapy for sickle cell disease remains a tough business model — and may never work

Biotech Adam Feuerstein and Jason Mast

STAT Plus: Pfizer pulls sickle cell treatment Oxbryta off global markets

Biotech Andrew Joseph

STAT Plus: Celldex drug reduces chronic hive activity, but patient discontinuations raise questions

Exclusive John Wilkerson and Rachel Cohrs Zhang

STAT Plus: Generic drug lobby taps former BIO exec as new CEO

The Readout Elaine Chen

STAT Plus: The science behind Summit’s success, 23andMe’s fate, and more biotech news updates

Matt's Take Matthew Herper

STAT Plus: Can Anne Wojcicki save 23andMe?

Exclusive Jonathan Wosen

STAT Plus: The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions

Biotech Jonathan Wosen and Allison DeAngelis

STAT Plus: Amgen scores late-stage trial success for eczema and myasthenia gravis treatments, but faces stiff competition

Biotech Stella Tannenbaum — The Boston Globe

STAT Plus: Bluebird Bio is laying off 25% of its workers to cut costs

Health tech Mohana Ravindranath

STAT Plus: Can AI reduce health care fraud, AI firm in Texas AG’s crosshairs, and more

Politics Rachel Cohrs Zhang and Elaine Chen

STAT Plus: Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices

Biotech Matthew Herper

STAT Plus: Amid push to redefine itself, Sanofi names new chief scientific officer

The Readout Elaine Chen

STAT Plus: Metsera’s GLP-1 drug has potential for monthly dosing, new data show

Biotech Adam Feuerstein

STAT Plus: Regeneron’s Eylea biosimilar fight heats up

Biotech Brittany Trang

STAT Plus: Novartis strikes AI drug development deal with Generate:Biomedicines

Biotech Adam Feuerstein

STAT Plus: Risky bet by Biogen and UCB on systemic lupus drug appears to pay off, data show

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to start the week

Exclusive Rachel Cohrs Zhang

STAT Plus: A mysterious anti ‘Big Pharma’ bus is barnstorming swing states

Politics John Wilkerson

STAT Plus: Wegovy is among drugs set to be targeted in the next round of Medicare price negotiations, researchers say

Pharma Rachel Cohrs Zhang

STAT Plus: PhRMA scores a small win in legal challenge to Medicare’s drug price negotiation

Biotech Elaine Chen

STAT Plus: Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects

The Readout Meghana Keshavan

STAT Plus: Are generalist investors good or bad for biotech?

Biotech Brittany Trang and Jason Mast

STAT Plus: Ginkgo Bioworks bets on protein AI model and data generation to turn struggling company around

Exclusive John Wilkerson

STAT Plus: Cassidy seeks to exempt small biotechs from Medicare drug price negotiation 

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Corbus shares will soar or dive soon. Here’s why

The Readout Elaine Chen

STAT Plus: The Fed cut rates and biotech stocks… didn’t do much